drugset / Trial / NCT02805829
Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
This trial is to evaluate the safety and effectiveness of activated and expanded in vitro autologous NK cells following trastuzumab treatment for patients Human Epidermal Receptor-2 overexpressing advanced gastric cancer.
Timeline
- Start
- 2017-01
- Primary completion
- 2020-01
- Completion
- 2020-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TROCULEUCEL | Cell therapy | — | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |